Bo Tang
Urology researcher at West China Hospital and first author of a study explaining how kidney cancers escape mTOR inhibitor drugs, and how blocking NEK7 restores their effect
Department of Urology, Institute of Urology, West China Hospital, Sichuan University (2026, at the time of the study)
Everolimus and temsirolimus, two drugs that block mTOR, are used for advanced clear cell renal cell carcinoma, the most common kidney cancer. Many tumours stop responding to them. In the Atlas study TAN2026 in Nature Communications, Bo Tang was first author of work that traces one escape route. The protein SPOP attaches a K63-linked chain of ubiquitin, a small tag protein, to ZMYND8. The tag keeps ZMYND8 out of phase-separated droplets, small membrane-less compartments inside the nucleus. Freed ZMYND8 pairs with ZHX2 to switch on the gene for NEK7, and NEK7 activates p70S6K, a growth kinase normally downstream of mTOR, by a route that mTOR drugs cannot block. A PROTAC, a molecule built to make the cell destroy a chosen protein, aimed at NEK7 restored sensitivity to everolimus. The evidence comes from cells and animal models, not from patients.
PubMed lists Tang at the Department of Urology and Institute of Urology of West China Hospital, Sichuan University in Chengdu. Because the name is very common, no other paper was tied to this person with enough confidence to include, and no official profile page was found.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2026 | A | SPOP-mediated ZMYND8 ubiquitination and phase separation exclusion drives mTOR inhibitor resistance in kidney cancer TAN2026 First author: showed that SPOP-driven ubiquitination of ZMYND8 switches on NEK7 and lets kidney cancer cells activate p70S6K without mTOR, and that a NEK7 degrader restores everolimus sensitivity. |
Co-authors in the Atlas 1
People with a profile here who share at least one study with Bo Tang.
ShowHide
- Haojie Huang Senior/corresponding author of a 2026 Nature Communications study identifying the SPOP–ZMYND8–NEK7 mechanism of mTOR-inhibitor resistance in kidney cancer
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.